Physician profile
Yongge Liu
NPI 1215153465
$15,056.30
in general payments reported to CMS, 2019-2025
55 companies · $3,364 in 2025
The $3,364 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $1,090 · 2021: $1,946 · 2022: $2,096 · 2023: $2,882 · 2024: $2,525 · 2025: $3,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,770.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,123.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,050.35 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Novo Nordisk INC | $2,009.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,106.31 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $953.03 | 2019-2025 | |
| Amgen INC. | $951.20 | 2019-2025 | Repatha, Evenity, Prolia |
| Otsuka America Pharmaceutical, INC. | $727.39 | 2022-2025 | Rexulti, Abilify Maintena |
| Viiv Healthcare Company | $441.75 | 2024-2025 | Apretude, Dovato, Cabenuva |
| Bayer Healthcare Pharmaceuticals INC. | $411.72 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $400.85 | 2019-2025 | Invega Sustenna, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.13 | 2019-2024 | Xifaxan, Trulance |
| Astellas Pharma US INC | $314.61 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $243.51 | 2019-2025 | Shingrix, Trelegy Ellipta, Pediarix |
| Ardelyx, INC. | $239.18 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $198.97 | 2021-2025 | Freestyle Libre 3 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yongge Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.